James Rossetti is an Oncology physician affiliated with UPMC Hillman Cancer Center. OpenAlex indexes 85 publications with 657 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20252 payments
- BeOne Medicines USA, Inc.Program year20251 payment
- ABBVIE INC.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.8%Kinase inhibitor13.5%Jakafi38%Brukinsa15%Vonjo14%Calquence12%Tasigna12%Imbruvica8%Part D<11 patientsThalidomide Analog5.1%Pomalyst37%Lenalidomide32%Revlimid31%Part D<11 patients+ 6 more classes in this area
Dermatology
25%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor25%Acyclovir100%Part D≥84 patientsMetabolism & gastrointestinal
16.7%Proton pump inhibitor6.5%Pantoprazole Sodium100%Part D≥21 patientsCorticosteroid3.9%Prednisone100%Part D≥23 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment patterns and outcomes in pacritinib-treated patients with MF and higher platelet count: MY-PAC study.
Journal of Clinical Oncology
2026 - Real-world outcomes of cytarabine consolidation in older patients with acute myeloid leukemia.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Diwakar Davar, MBBS, MSc
UPMC Hillman Cancer Center
Michal Krauze
UPMC Hillman Cancer Center
David Weksberg, MD
UPMC Hillman Cancer Center
Anastasios Raptis
UPMC Hillman Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”